EU needlestick injuries initiative shelved again:
This article was originally published in Clinica
For the second time in a fortnight, the European Parliament has had to shelve voting on a demand for EU legislation to reduce the estimated 1 million needlestick injuries reported annually by health professionals (see Clinica No 1209, p 2). Once more, it was bad timing that prevented a vote, since the item was again listed last on the agenda, and MEPs began deserting the chamber for lunch. It was considered unlikely that the necessary "supermajority" of 732 serving members could be reached, so an application has been made for the proposal to be referred back to the Employment and Social Affairs Committee, to wait for a more favourable voting slot.
You may also be interested in...
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.